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The aim of the present study was to investigate changes in blood glucose concentration ([Glu]B), acid–
base status and electrolyte concentrations during constant rate infusions (CRI) of two alpha2-adrenergic
agonists in seven horses treated in a blinded, randomised, crossover design with xylazine or romiﬁdine.
An intravenous (IV) bolus of xylazine (1 mg/kg) or romiﬁdine (80 lg/kg) was administered followed by an
IV CRI of xylazine (0.69 mg/kg/h) or romiﬁdine (30 lg/kg/h) for 2 h. Blood samples were collected from
the pulmonary artery before and after loading doses, during the CRI, and for 1 h after discontinuing drugs.
Blood glucose, base excess (BE), pH, partial pressure of carbon dioxide (PvCO2), strong ion difference
(SIDest) and bicarbonate concentration (½HCO3 stdB) increased signiﬁcantly during the CRI with both
alpha2-adrenergic agonists. Chloride concentration ([Cl]B) and anion-gap (AG) decreased signiﬁcantly
compared to baseline. The decrease in sodium concentration ([Na+]B) was only signiﬁcant with xylazine.
From 1 h after starting the CRI onwards, [Glu]B was signiﬁcantly higher with romiﬁdine compared to
xylazine. Except [Glu]B, SIDest, and PvCO2, all variables returned to normal values 1 h after discontinuing
xylazine. After stopping romiﬁdine, all variables except pH remained altered for at least 1 h.
It was concluded that loading doses of alpha2-adrenergic agonists followed by CRIs produce [Glu]B,
acid–base and electrolyte changes. The clinical signiﬁcance of the reported changes remains to be inves-
tigated and absolute values should be interpreted with caution, as ﬂuid boli were used for cardiac output
measurements, but may become important during prolonged infusion and in critically ill patients.
 2013 Elsevier Ltd. All rights reserved.
Introduction
Alpha2-adrenergic agonists are routinely used for sedation and
analgesia in veterinary medicine (Dart, 1999) and administration
as an intravenous (IV) constant rate infusion (CRI) is becoming
more frequent (Lamont et al., 2012; Ringer, 2012). The main
advantages of alpha2-adrenergic agonists in humans are the potent
sedative and analgesic effects with minimal respiratory depression
and less postoperative delirium compared to other drugs (Hoy and
Keating, 2011). In human intensive care units (ICUs) interest in CRI
of alpha2-adrenergic agonists is increasing (Tan and Ho, 2010; Hoy
and Keating, 2011). This tendency is also observed in veterinary
critical care patients (Posner and Burns, 2009).
Concerns regarding alpha2-adrenergic agonists mainly reﬂect
their cardiovascular (CV) effects (England and Clarke, 1996; Mur-
rell and Hellebrekers, 2005; Tan and Ho, 2010), and many studies
have been designed to examine the CV effects of alpha2-adrenergic
agonist CRIs in horses (Bettschart-Wolfensberger et al., 1999; Ring-
er et al., 2013a). However, the use of alpha2-adrenergic agonists is
also associated with other side effects that might be less obvious,
but may have important consequences, especially in critically ill
patients. For example, hyperglycaemia is associated with worse
outcomes in proportion to the elevations in blood glucose concen-
tration ([Glu]B) in human medicine (Klonoff, 2011). Hyperglyca-
emia is also associated with diuresis, which has been described
following single doses of alpha2-adrenergic agonists in horses
(England and Clarke, 1996) and other species (Ambrisko and Hika-
sa, 2002; Kanda and Hikasa, 2008; Talukder and Hikasa, 2009;
Murahata and Hikasa, 2011).
Despite the increasing use of alpha2-adrenergic agonists,
including in critically ill animals (Posner and Burns, 2009), changes
in [Glu]B, electrolyte concentrations and acid–base status during
CRIs of alpha2-adrenergic agonists remain insufﬁciently studied.
Additionally, the different alpha2-adrenergic agonists used as a
CRI have not been compared regarding their effects on [Glu]B,
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electrolytes and acid–base status. Xylazine and romiﬁdine are both
registered alpha2-adrenergic agonists commonly used in equine
clinical practice. Romiﬁdine is more alpha2 receptor-selective than
xylazine or detomidine, but less than medetomidine (Muir, 2009).
The aim of the present study was to investigate the effects of xyla-
zine and romiﬁdine CRIs on [Glu]B, acid–base balance and electro-
lytes in horses, and to compare the two drugs.
Materials and methods
The study was approved by the Ethical Committee of the National Veterinary
School of Lyon (0807, 13 May 2008) and was performed using blood samples ob-
tained during a cardiovascular study reported elsewhere (Ringer et al., 2013a).
For the concurrent cardiovascular study, seven research horses (six French Stan-
dardbreds and one French Saddlebred; 8.7 ± 1.75 years; 515.2 ± 52.96 kg) were
catheterised with Swan-Ganz thermodilution catheters placed in the pulmonary
arteries. The catheters were advanced through 8.5F introducer sheaths (Intro-ﬂex,
Edwards Lifesciences) that had been previously placed in the jugular vein.
After catheterisation, two baseline blood samples (B1, B2) were collected
10 min apart from the pulmonary artery. Blood samples were collected anaerobi-
cally into blood gas syringes (BD A-Line, BD Diagnostics) and immediately analysed
using a point-of-care blood gas system including a co-oximeter (Rapidpoint 400,
Siemens Medical Solutions Diagnostics).
Blood gases were analysed at 37 C without correcting for the horses’ tempera-
ture. The blood gas analyser measured pH, partial pressure of carbon dioxide
(PvCO2), [Glu]B, and blood electrolyte concentrations (sodium [Na+]B, chloride [Cl]B,
and potassium [K+]B). The anion gap (AG), standard bicarbonate concentration
½HCO3 stdB, and base excess of the extracellular compartment (BEecf) were calcu-
lated automatically by the analyser. Strong ion difference was estimated (SIDest)
by manual calculation using the formula: SIDest = [Na+]B  [Cl]B. Preliminary refer-
ence values for the blood gas analyser were determined including 15 healthy horses
and were deﬁned as means ± 2 SD.
Horses were treated in a blinded, randomised, crossover design with xylazine or
romiﬁdine. A 16-day washout period was allowed between treatments. After base-
line measurements, horses were sedated with xylazine (Xylasol, Dr. E. Graeub)
(1 mg/kg) or romiﬁdine (Sedivet, Boehringer Ingelheim) (80 lg/kg) given IV over
3 min by manual injection through the side arm of one of the introducer sheaths.
The start of the loading dose administration was time point 0. Loading doses were
followed by xylazine (0.69 mg/kg/h) or romiﬁdine (30 lg/kg/h) CRI for 2 h (time
points 3–123 min). The CRIs were delivered by infusion pumps (Syramed
lSP6000, Arcomed). Drugs were diluted in 0.9% saline (Chlorure de Sodium 0.9%;
Braun Medical) by an unblinded person, so that equal volumes (50 mL loading dose,
25 mL/h CRI) were administered in both treatments.
Beside the CRIs containing alpha2-adrenergic agonists in 0.9% NaCl, the horses
did not receive any oral or IV ﬂuids throughout the duration of the study, with
the exception of repeated boluses of ice-cold ﬂuids (5% glucose [Braun Medical]
in ﬁve horses, 0.9% NaCl in two horses) used for cardiac output measurements by
thermodilution conducted within the concurrent CV study. Administered bolus
doses resulted in average (mean ± SD) 5% glucose doses per hour of 1.3 ± 0.61 mL/
kg/h (xylazine treatment) and 1.3 ± 0.65 mL/kg/h (romiﬁdine treatment). The aver-
age 0.9% NaCl dose was 1.2 ± 0.64 mL/kg/h (xylazine) and 1.4 ± 0.48 mL/kg/h (romi-
ﬁdine). Cardiac output measurements were done at each time point, always after
blood collection. The horses received the same type of ﬂuid during both treatments.
Blood analyses were repeated immediately after ﬁnishing loading dose admin-
istration (3 min) and thereafter every 10 min during the ﬁrst hour of CRI (13, 23, 33,
43, 53, 63 min) and every 15 min during the second hour (78, 93, 108, 123 min). The
CRIs were discontinued after 2 h (time point 123 min) and data were collected
every 15 min for an additional hour (138, 153, 168, and 183 min).
Statistical methods
As there was no difference in results when the horses receiving glucose for car-
diac output measurements were analysed separately from the ones receiving saline,
data of all seven horses were pooled for statistical analysis. Statistical analysis was
performed using SigmaStat 3.5 (Systat Software). Homogeneity of variances was as-
sessed by graphical display of the data and validity of the normality assumption
was conﬁrmed by assessment of normal probability plots of the residuals. Two-
way repeated measures ANOVA (two within factors) followed by a Holm–Sidak test
for multiple comparisons versus a control (time point B1) was used to compare the
two treatments and to study changes over time compared to baseline. The level of
signiﬁcance was set at P < 0.05.
Results
A signiﬁcant increase in [Glu]B was observed during both
alpha2-adrenergic agonist infusions (Treatment, P = 0.001; Time,
P < 0.001; Treatment  Time, P < 0.001) (Fig. 1). The increase was
more pronounced with romiﬁdine compared to xylazine. An in-
crease in [Glu]B was also observed in horses receiving 0.9% NaCl in-
stead of 5% glucose for cardiac output measurements (Fig. 1).
Signiﬁcant changes in pH were seen over time and between
treatments (Treatment, P = 0.007; Time, P < 0.001; Treat-
ment  Time, P = 0.330) (Fig. 2). There was a signiﬁcant increase
in pH with both alpha2-adrenergic agonists. Overall and already
at baseline, pH was signiﬁcantly higher with romiﬁdine compared
to xylazine. Also, a signiﬁcant increase in BEecf (Treatment,
P = 0.156; Time, P < 0.001; Treatment  Time, P < 0.001) and
½HCO3 stdB (Treatment, P = 0.057; Time, P < 0.001; Treat-
ment  Time, P < 0.001) was observed during both alpha2-adrener-
gic agonists (Fig. 2). After discontinuing CRIs, the effects on BEecf
and ½HCO3 stdB were longer lasting with romiﬁdine compared to
xylazine. During drug administration, a progressive, signiﬁcant in-
crease in PvCO2 (Treatment, P = 0.40; Time, P < 0.001; Treat-
ment  Time, P = 0.008) was seen with both treatments (Fig. 2).
With romiﬁdine the PvCO2 remained increased 1 h after discon-
tinuing CRI.
With both alpha2-adrenergic agonists a signiﬁcant decrease in
[Cl]B was observed (Treatment, P = 0.080; Time, P < 0.001; Treat-
ment  Time, P < 0.001) (Fig. 3). Effects on [Cl]B were more pro-
longed with romiﬁdine. A signiﬁcant decrease in [Na+]B was
detected over time for xylazine, but not for romiﬁdine (Treatment,
P = 0.021; Time, P = 0.056; Treatment  Time, P = 0.031) (Fig. 3).
Already at baseline, [Na+]B values were signiﬁcantly lower with
romiﬁdine compared to xylazine, and remained signiﬁcantly lower
at different measurement points. No signiﬁcant changes over time
or between treatments were seen for [K+]B (Treatment, P = 0.080;
Time, P = 0.951; Treatment  Time, P = 0.216) (Fig. 3).
There were no signiﬁcant differences in SIDest between treat-
ments, but with both alpha2-adrenergic agonists a signiﬁcant in-
crease over time was observed (Treatment, P = 0.594; Time,
P < 0.001; Treatment  Time, P = 0.057) (Fig. 4). With xylazine
there was a signiﬁcant decrease in AG during drug administration,
while with romiﬁdine a decrease in AG was only observed 1 h after
drug discontinuation (Treatment, P = 0.845; Time, P < 0.001; Treat-
ment  Time, P = 0.002) (Fig. 4). A signiﬁcantly lower AG was
Fig. 1. Blood glucose concentration ([Glu]B: mean ± SD) measured before loading
doses of xylazine and romiﬁdine (B1, B2), immediately after loading dose
administration (3 min), during 2 h of CRI (3–123 min), and for 1 h after discon-
tinuing CRI (123–183 min). Five horses received 5% glucose (continuous lines) and
two received 0.9% NaCl (dashed lines) for cardiac output measurements. Dotted
area shows drug administration time. Signiﬁcant difference (Holm–Sidak,
P < 0.05) compared to the baseline (B1) of the same treatment. s Signiﬁcant
difference (Holm–Sidak, P < 0.05) between treatments Blue lines represent
(mean ± 2 SD) values obtained in 15 healthy horses.
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observed with xylazine compared to romiﬁdine at the end of CRI
(123 min). After discontinuing CRI, with xylazine the AG increased
rapidly, leading to a higher AG compared to romiﬁdine at 183 min.
Discussion
The results of this study indicate that both xylazine and romiﬁ-
dine signiﬁcantly alter [Glu]B, electrolyte concentrations and acid
base balance when administered as a bolus followed by a CRI dur-
ing 2 h in healthy horses.
An increase in [Glu]B has been described in the horse after
administration of single doses of different alpha2-adrenergic ago-
nists (England and Clarke, 1996) and during detomidine CRI com-
bined with buprenorphine (van Dijk et al., 2003). However, to our
knowledge this is the ﬁrst time effects on [Glu]B were studied dur-
ing CRIs of alpha2-adrenergic agonists as sole agents in horses.
Postsynaptic alpha2-adrenergic receptors of the pancreatic
b-cells are involved in insulin regulation (Ruohonen et al., 2012)
and probably play an important role in the hyperglycaemic effect
of alpha2-adrenergic agonists. However, other authors have sug-
gested that the effects of alpha2-adrenergic agonist on glycaemic
response are not only due to actions mediated by alpha2-adrener-
gic receptors (Ambrisko and Hikasa, 2002; Kanda and Hikasa,
2008). Other sites of action (e.g. hepatic tissue) and involvement
of other receptors such as alpha1-adrenergic receptors and imidaz-
oline receptors have been proposed (Ambrisko and Hikasa, 2002;
Kanda and Hikasa, 2008).
In the present study, the increase in [Glu]B was more pro-
nounced with romiﬁdine compared to xylazine. Differences in
hyperglycaemic response between different alpha2-adrenergic
agonists have already been described in dogs and cats (Ambrisko
and Hikasa, 2002; Kanda and Hikasa, 2008). It has been hypothe-
sised that the high alpha2-adrenergic selectivity of medetomidine
compared to other alpha2-adrenergic agonists is most likely
responsible for its less pronounced (i.e. non-signiﬁcant) effect on
plasma glucose concentration in dogs (Burton et al., 1997). How-
ever, this is not in agreement with the results of the present study
where romiﬁdine, the more alpha2-selective drug, produced a
more pronounced effect on hyperglycaemia compared to xylazine.
In human medicine, hyperglycaemia from any cause is associ-
ated with worse outcomes in proportion to the elevations in [Glu]B
(Klonoff, 2011). In the present study, [Glu]B appeared to increase
continuously during CRI and to decrease only once alpha2-adrener-
gic agonists were discontinued. Therefore, even higher [Glu]B can
be expected during more prolonged infusions. Absolute values of
the present study should be interpreted with caution, as some
horses received repeated boli of 5% glucose solution for cardiac
output measurements. In two horses, normal saline was used in-
stead, to see if changes in [Glu]B were only due to the glucose solu-
tion used for cardiac output measurement. In these two horses not
receiving 5% glucose solution, an increase in [Glu]B was also ob-
served, and the increase was larger with romiﬁdine compared to
xylazine (Fig. 1). Also, the fact that [Glu]B decreased after discon-
tinuing alpha2-adrenergic agonists despite continuing cardiac out-
put measurements indicates that the increase observed during
Fig. 2. Measurements of pH, mixed venous partial pressure of carbon dioxide (PvCO2), base excess (BE) and blood bicarbonate (½HCO3 stdB) concentration (mean ± SD) in
seven horses before loading doses of xylazine and romiﬁdine (B1, B2), immediately after loading dose administration (3 min), during 2 h of CRI (3–123 min), and for 1 h after
discontinuing CRI (123–183 min). Dotted area shows drug administration time. , s Key in Fig. 1. Both treatments signiﬁcant difference compared to baseline (B1). Blue
lines represent (mean ± 2 SD) values obtained in 15 healthy horses.
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alpha2-adrenergic agonist CRI was not only due to 5% glucose
administration.
Blood electrolyte concentrations were studied during 3 h of
medetomidine–morphine CRI and no signiﬁcant changes were
seen in Na+, K+ and Cl (Solano et al., 2009). In the present study,
a continuous and signiﬁcant decrease in [Cl]B and increase in
SIDest was observed during both CRIs. However, the decrease in
[Na+]B was only signiﬁcant with xylazine. The SIDest can increase
due to an increase in plasma Na+ concentration, a decrease in Cl
concentration, or a decrease in plasma free water (commonly
dehydration) (Autran de Morais and Constable, 2012). Dehydration
and hypernatremia are unlikely, since a decrease rather than an in-
crease in [Na+]B concentration was observed in the present study.
Therefore, the increase in SIDest is mostly attributed to the decrease
in [Cl]B. A decrease in serum [Cl]B has not been reported after
alpha2-adrenergic agonist administration before. However, an in-
creased excretion of Cl was observed after xylazine bolus admin-
istration in horses (Trim and Hanson, 1986).
Effects of alpha2-adrenergic agonists on Cl transport have been
demonstrated on human cystic ﬁbrosis epithelial and colonic cell
lines (Holliday et al., 1997; Norez et al., 2008). However, urinary
electrolyte concentrations and fractional excretion of electrolytes
in the urine were not investigated in the present study and the ex-
act mechanism leading to the observed electrolyte changes in
horses cannot be elucidated. A compensatory hypochloraemic
alkalosis in response to the increased PvCO2 is unlikely, as there
was a simultaneous increase in pH, which would mean that over-
compensation had occurred, and this is improbable. Nevertheless,
it is interesting that this is the ﬁrst time that a decrease in [Cl]B
has been described related to alpha2-adrenergic agonists.
Fig. 3. Measurements of blood sodium [Na+]B, chloride [Cl]B, and [K+]B concentra-
tions (mean ± SD) before loading doses of xylazine and romiﬁdine (B1, B2),
immediately after loading dose administration (3 min), during 2 h of CRI
(3–123 min), and for 1 h after discontinuing CRI (123–183 min). Five horses
received 5% glucose solution (continuous lines) and two received 0.9% NaCl (dashed
lines) for cardiac output measurements. Dotted area shows drug administration
time. , s Key in Fig. 1. Blue lines represent (mean ± 2 SD) values obtained in 15
healthy horses.
Fig. 4. Estimated strong ion difference (SIDest) and anion gap (AG) (mean ± SD)
measured in seven horses before loading doses of xylazine and romiﬁdine (B1, B2),
immediately after loading dose administration (3 min), during 2 h of CRI (3–
123 min), and for 1 h after discontinuing CRI (123–183 min). Dotted area shows
drug administration time. , s Key in Fig. 1. Both treatments signiﬁcant
difference compared to baseline (B1) Blue lines represent (mean ± 2 SD) values
obtained in 15 healthy horses.
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Contrary to our results observed with xylazine, no decrease or
even a signiﬁcant increase in serum Na+ concentration has been
observed in other studies using different single doses of alpha2-
adrenergic agonists (Thurmon et al., 1984; Trim and Hanson,
1986; Gasthuys et al., 1993; Kullmann et al., 2011; Wojtasiak-Wy-
part et al., 2012). Nevertheless, an increased Na+ excretion in urine
has been described for horses after romiﬁdine (Gasthuys et al.,
1993). No changes in [K+]B were observed in the present study.
However, effects on serum concentration and urinary excretion
of K+ have been described after single doses of xylazine and romi-
ﬁdine (Trim and Hanson, 1986; Wojtasiak-Wypart et al., 2012).
In our study, a decrease in AG was observed, although with
romiﬁdine, the decrease was only signiﬁcant 1 h after discontinu-
ing CRI. Hypoalbuminaemia is considered the only important cause
for a decrease in AG (Autran de Morais and Leisewitz, 2012),
although an accumulation of unmeasured cations (e.g., hypercalca-
emia, hyperkalaemia and hypermagnesaemia) should be consid-
ered as well (Rennke and Denker, 2007). In the present study,
there were no signiﬁcant changes in [K+]B and a decrease, rather
than an increase in Ca2+ has been previously reported after romiﬁ-
dine administration (Wojtasiak-Wypart et al., 2012). However, a
decrease in total plasma solids has been described during detomi-
dine CRI (Daunt et al., 1993) and a decrease in total proteins during
medetomidine/morphine CRI (Solano et al., 2009). Unfortunately,
plasma proteins, albumin, Ca2+ and Mg2+ were not measured in
the present study.
A signiﬁcant increase in pH, BEecf, ½HCO3 stdB, and PvCO2 was
observed during both treatments. However pH values remained
within physiologically normal limits. An increase in pH has not
been reported previously after single doses of the different alpha2-
adrenergic agonists (Clarke et al., 1991; Bueno et al., 1999;
Yamashita et al., 2000; Freeman et al., 2002; Bettschart-Wolfens-
berger et al., 2005) or during CRI of medetomidine and detomidine
(Daunt et al., 1993; Bettschart-Wolfensberger et al., 1999; van Dijk
et al., 2003) in horses. Conversely, a decrease in pH in face of an in-
crease in HCO3 was reported during a CRI of medetomidine–mor-
phine (Solano et al., 2009). However, the horses of Solano et al.
(2009) underwent laparoscopy with insufﬂation of carbon dioxide,
which was accompanied by a signiﬁcant increase in PaCO2.
In this study, the increase in pH observed in face of an increase
in PvCO2, associated with an increase in BE and SIDest and a de-
crease in AG, were indicative of metabolic alkalosis. As already
mentioned before, the increase in SIDest was probably due to a de-
crease in [Cl]B. Therefore, hypochloraemic metabolic alkalosis was
suspected, resulting from an increase in blood ½HCO3 stdB second-
ary to loss of Cl from the body. A signiﬁcant increase in
½HCO3 stdB was observed for both alpha2-adrenergic agonists. Sim-
ilar effects on HCO3 and BE have been observed after single doses
of romiﬁdine (Freeman et al., 2002; Wojtasiak-Wypart et al., 2012)
or during medetomidine or detomidine CRI (Daunt et al., 1993;
Bettschart-Wolfensberger et al., 1999; Solano et al., 2009) in
horses. Unfortunately blood lactate was not measured in the pres-
ent study. However, based on the rather elevated BE and pH we do
not expect an important increase in lactate. This would coincide
with previous studies reporting no changes in blood lactate after
single doses or CRIs of alpha2-adrenergic agonists in horses (Solano
et al., 2009; Kullmann et al., 2011).
The signiﬁcant differences seen between the two alpha2-adren-
ergic agonists in the present study might be attributed to the
speciﬁcity or selectivity for different subtypes of alpha2-adrenergic
receptors or collateral effects on other receptors like imidazoline or
alpha1-adrenergic receptors, or due to a complex interaction of dif-
ferent mechanisms. The difference might also be dose-dependent.
However, the two protocols used in the present study provided the
same depth of sedation during CRI, as assessed by the head
position in relation to the ground in undisturbed healthy horses
(Ringer et al., 2013b). The more prolonged effect of romiﬁdine
compared to xylazine after discontinuing drug administration is
not surprising, as a prolonged effect of romiﬁdine compared to
xylazine has already been shown for sedation and cardiovascular
effects (Ringer et al., 2013a,b).
The main limitation of the present study is the use of ﬂuid boli
for cardiac output measurements of a concomitant study. This
could have had an effect on our absolute values, however not on
the comparison between the two treatments, as each individual
horse received the same ﬂuid during both treatments. Also the fact
that variables tended to normalise after discontinuing alpha2-
adrenergic agonists despite continuing cardiac output measure-
ments indicates, that changes were unlikely only due to ﬂuid boli.
The clinical importance of the changes we observed remains to
be investigated. However, fact is that with both alpha2-adrenergic
agonists mean values of several variables were outside the
mean ± 2 SD of the reference values obtained from 15 healthy
horses. With both alpha2-adrenergic agonists the changes observed
were increasing with duration of CRI. Therefore, aggravation of the
effects should be expected during more prolonged infusion. The in-
duced changes should probably also be considered in critically ill
patients with pre-existing disturbances in [Glu]B, electrolyte, and
acid–base balance, where further alterations in biochemical vari-
ables might be crucial. This is critical, as the use of alpha2-adrener-
gic agonist CRIs to provide sedation, anxiolysis and analgesia is
becoming more and more popular in human and small animal ICUs
(Posner and Burns, 2009; Tan and Ho, 2010; Hoy and Keating,
2011), and probably in the future also in equine intensive care
patients.
However, extrapolation of the present results to different popu-
lations should be done with caution, since the effects might de-
pend on the alpha2-adrenergic agonist used, its dose, the
duration of administration, the species and the underlying condi-
tion and metabolic status of the animal. Therefore, further studies
using the different alpha2-adrenergic agonist as a CRI in the differ-
ent species and under different conditions are recommended to
elucidate the relevance of alpha2-adrenergic agonist-induced met-
abolic changes in clinical patients.
Conclusions
Xylazine and romiﬁdine administered as a CRI had signiﬁcant
effects on [Glu]B, electrolyte concentrations, and acid–base status
in horses. Changes become progressively more prominent during
CRI, and should be considered in patients receiving prolonged
alpha2-adrenergic agonist infusions.
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